The Recall Desk
ModerateFDA (Drugs)·D-1613-2020·Announced 2020-09-23

RLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations

RLC Labs Inc. is recalling WP Thyroid tablets because they were manufactured under conditions found to be subpotent. The recall covers lots expiring between October 2020 and July 2023.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, which typically involves a reasonable probability of temporary or medically reversible adverse health consequences. The source text does not report specific illnesses or injuries, aligning with a moderate severity rating for a CGMP deviation involving subpotency.

Plain-English summary

RLC Labs Inc. is recalling WP Thyroid, Westhroid Pure, 2 Grain (130 mg) Thyroid USP tablets. The recall is due to Current Good Manufacturing Practice (CGMP) deviations, specifically that the product was manufactured under the same conditions as those found to be subpotent.

The affected product is available in 30, 60, 90, 100, and 1,000 tablet packages. The recall includes all lots with expiration dates between October 2020 and July 2023. The product was distributed nationwide in the United States.

Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on next steps.

The recalled product

Product
WP Thyroid, Westhroid Pure, 2 Grain (130 mg) Thyroid USP packaged in a) 1,000 Tablets, NDC 64727-5950-2 ; b) 30 Tablets, NDC 64727-5950-4; c) 60 Tablets, NDC 64727-5950-5; d) 90 Tablets, NDC 64727-5950-6; e) 100 Tablets, NDC 64727-5950-1; Rx Only, Manufactured by: RLC Labs Phoeni
Manufacturer
RLC Labs Inc.
Category
Drug — Thyroid Medication
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots with expiry between 10/2020-07/2023

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 24 products in this recall →

Related recalls

Same manufacturer · RLC Labs Inc.

See all →

Same hazard · subpotency

See all →